Preeclampsia remains a major complication in pregnancies affected by T1DM. A retrospective cohort study from a tertiary center in Poland, published in Diabetes Research and Clinical Practice, explored whether first-trimester CGM metrics could help identify women at higher risk.

The analysis included 70 women with T1D using sensor-augmented insulin pump therapy who initiated CGM by 13 weeks of gestation. Thirteen participants (18.6%) developed preeclampsia. Those affected showed higher first-trimester mean glucose levels (121.6 vs 112.3 mg/dL; p = 0.0012), lower time-in-range (63.3% vs 70.2%; p = 0.03), and a trend toward greater glucose variability (CV 38.4% vs 34.3%; p = 0.055). Glycemic control was similar between groups in later trimesters.

These findings suggest that early CGM metrics, particularly mean glucose and time-in-range, may aid in identifying pregnant women with T1D who are at increased risk of preeclampsia. Larger prospective studies are needed to confirm these associations and to determine their clinical role in pregnancy risk stratification.